CompumedicsASX:CMP +2.00%61 EBITDA Margin % is 9.99% as of Dec. 2025, which is 33% above its 10-year median of 7.51. GuruFocus rates ASX:CMP with a GF Score™ of 61/100 and a GF Value™ of A$0.31 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Compumedics ranks better than 54.17% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Compumedics's EBITDA for the
six
months ended in Dec. 2025 was A$3.09 Mil. Compumedics's Revenue for the
six
months ended in Dec. 2025 was A$30.98 Mil. Therefore, Compumedics's EBITDA margin for the quarter that ended in Dec. 2025 was 9.99%.
Compumedics (ASX:CMP) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Compumedics EBITDA Margin % Related Terms
Compumedics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Compumedics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CMP vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Compumedics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Compumedics EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Compumedics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Compumedics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Compumedics (ASX:CMP) has a EBITDA Margin % of 9.99% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Compumedics and its competitors. This is 33% above median its historical median of 7.51. According to the industry distribution chart, Compumedics ranks #374 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 45.8%.
Is Compumedics' EBITDA Margin % too high?
Compumedics' current EBITDA Margin % of 9.99% is 33% above median its 10-year median of 7.51. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Compumedics' value of 9.99% is 33.6% above this industry median. Based on the distribution chart, Compumedics ranks #374 out of 816 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Compumedics has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Compumedics' EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Compumedics ranks #374 out of 816 companies for EBITDA Margin %. This puts Compumedics in the upper half of its industry. The industry median EBITDA Margin % is 7.48. Compumedics' value of 9.99% is 33.6% above this benchmark. While the company's 10-year median is 7.51 vs. the industry median of 7.48, Compumedics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Compumedics's current EBITDA Margin % of 9.99% is 33.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Compumedics and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Compumedics's current EBITDA Margin % is 9.99%, which is 33% above median its own 10-year median of 7.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compumedics stock overvalued right now?
Based on GuruFocus' analysis, Compumedics (ASX:CMP) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.31, compared to a current price of A$0.26 — trading 17.7% below its estimated fair value. The current EBITDA Margin % is 9.99%, which is 33% above median its 10-year median of 7.51 and 33.6% above the Medical Devices & Instruments industry median of 7.48. Compumedics' overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Compumedics (ASX:CMP), the current EBITDA Margin % is 9.99% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Compumedics (ASX:CMP) Overvalued in 2026?
Based on GuruFocus' analysis, Compumedics stock appears to be undervalued.
The current stock price of A$0.26 is trading 17.7% below its estimated GF Value™ of A$0.31.
GuruFocus considers Compumedics to be Modestly Undervalued.
Key valuation signals for ASX:CMP:
EBITDA Margin %: 9.99% (33% above median its 10-year median of 7.51)
GF Value™: A$0.31 vs. price of A$0.26 (17.7% below fair value)
Industry Position: 33.6% above the Medical Devices & Instruments median (#374 of 816)
No single metric tells the full story. See the ASX:CMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Compumedics Ltd is a medical device company. It is engaged in the development, manufacturing, and commercialization of diagnostic technologies for sleep, brain, and ultrasonic blood-flow monitoring applications. The company is organized into geographical operating segments, being the United States of America, Australia and Asia Pacific, and Europe and the Middle East. It derives a majority of its revenue from Australia and the Asia Pacific region.
61GF Score
Get the complete analysis for ASX:CMP
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CMP has been successfully added to your 
